Natural Products as the Modulators of Gut Microbiota: A Pool for the Development of New Treatment Against Obesity?

IF 6.9 Q1 FOOD SCIENCE & TECHNOLOGY
Food frontiers Pub Date : 2026-04-10 DOI:10.1002/fft2.70275
Hongchao Yuan, Yau-Yuen Chan, Guang Chen, Lin Xu, Cheng Zhang, Guoyi Tang, Yibin Feng, Ning Wang
{"title":"Natural Products as the Modulators of Gut Microbiota: A Pool for the Development of New Treatment Against Obesity?","authors":"Hongchao Yuan,&nbsp;Yau-Yuen Chan,&nbsp;Guang Chen,&nbsp;Lin Xu,&nbsp;Cheng Zhang,&nbsp;Guoyi Tang,&nbsp;Yibin Feng,&nbsp;Ning Wang","doi":"10.1002/fft2.70275","DOIUrl":null,"url":null,"abstract":"<p>The global increase in obesity and related metabolic disorders calls for innovative treatment approaches that extend beyond traditional drug-based interventions. These conventional pharmacological methods are frequently associated with considerable adverse effects. This review synthesizes recent advances in understanding how natural products—including polyphenols, prebiotics, alkaloids, saponins, and polysaccharides—modulate gut microbiota to combat obesity. Key findings highlight that compounds like resveratrol, berberine, and <i>Panax notoginseng</i> saponins enhance beneficial microbial populations (e.g., <i>Akkermansia</i> and <i>Bifidobacterium</i>), promote short-chain fatty acid production, and restore intestinal barrier integrity, thereby ameliorating metabolic dysfunction. Clinical and preclinical studies demonstrate their potential to reduce adiposity, inflammation, and insulin resistance. However, challenges such as limited human trials, variability in gut microbiota composition, and standardization of natural products remain. This work advocates for further large-scale human studies to validate these findings, positioning natural products as promising, sustainable adjuvants in obesity management through microbiota-targeted therapies.</p>","PeriodicalId":73042,"journal":{"name":"Food frontiers","volume":"7 3","pages":""},"PeriodicalIF":6.9000,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://iadns.onlinelibrary.wiley.com/doi/epdf/10.1002/fft2.70275","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Food frontiers","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fft2.70275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The global increase in obesity and related metabolic disorders calls for innovative treatment approaches that extend beyond traditional drug-based interventions. These conventional pharmacological methods are frequently associated with considerable adverse effects. This review synthesizes recent advances in understanding how natural products—including polyphenols, prebiotics, alkaloids, saponins, and polysaccharides—modulate gut microbiota to combat obesity. Key findings highlight that compounds like resveratrol, berberine, and Panax notoginseng saponins enhance beneficial microbial populations (e.g., Akkermansia and Bifidobacterium), promote short-chain fatty acid production, and restore intestinal barrier integrity, thereby ameliorating metabolic dysfunction. Clinical and preclinical studies demonstrate their potential to reduce adiposity, inflammation, and insulin resistance. However, challenges such as limited human trials, variability in gut microbiota composition, and standardization of natural products remain. This work advocates for further large-scale human studies to validate these findings, positioning natural products as promising, sustainable adjuvants in obesity management through microbiota-targeted therapies.

Abstract Image

Abstract Image

天然产物作为肠道微生物群的调节剂:开发新的治疗肥胖的方法?
全球肥胖和相关代谢紊乱的增加要求创新治疗方法,超越传统的基于药物的干预。这些传统的药理学方法往往伴随着相当大的副作用。这篇综述综合了了解天然产物-包括多酚、益生元、生物碱、皂苷和多糖-如何调节肠道微生物群以对抗肥胖的最新进展。主要研究结果强调,白藜芦醇、小檗碱和三七皂苷等化合物可以增加有益微生物的数量(如阿克曼氏菌和双歧杆菌),促进短链脂肪酸的产生,恢复肠道屏障的完整性,从而改善代谢功能障碍。临床和临床前研究证明了它们在减少肥胖、炎症和胰岛素抵抗方面的潜力。然而,诸如有限的人体试验、肠道微生物群组成的可变性以及天然产物的标准化等挑战仍然存在。这项工作提倡进一步的大规模人体研究来验证这些发现,将天然产物定位为有前途的、可持续的辅助剂,通过微生物群靶向治疗来管理肥胖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.50
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书